SHANGHAI HENLIUS BIOTECH - ASTRIDE TRIAL SHOWS FAVORABLE MEDIAN OVERALL SURVIVAL FOR SERPLULIMAB VS ATEZOLIZUMAB

Reuters · 2d ago

Please log in to view news